Nevertheless, a Swedish Apolipoprotein Mortality Risk (AMORIS) study shows a different result, which is that a low level of ApoA1 and HDL may be a risk factor for prostate cancer patients. This evidence concerns the gene APOA1 and prostate carcinoma.